Marina S. Parisi
Catania, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.
Journal: Leukemia & lymphoma
Published: October 31, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study.
Journal: Journal of clinical medicine
Published: July 08, 2025
Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement.
Journal: European journal of haematology
Published: June 24, 2025
Real-World Outcomes in FLT3-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort.
Journal: Journal of clinical medicine
Published: June 22, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with Venetoclax.
Journal: Journal of clinical medicine
Published: June 02, 2025
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Journal: Annals of hematology
Published: February 25, 2024
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data.
Journal: Healthcare (Basel, Switzerland)
Published: April 23, 2023
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
Journal: Frontiers in immunology
Published: March 28, 2023
Last Updated: 09/26/2026